SCHEMBL1721091

SCHEMBL1721091

CCCn1c(-c2cccc(C(F)(F)F)c2)nc(=O)c2c1N=C(c1ccc(OC)cc1)[N]2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.43
NR1H4 Q96RI1 1/20 0.42
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 3/20 0.40
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ADORA2B P29275 3/20 0.39
HSD17B10 Q99714 1/20 0.38
PPARD Q03181 2/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAOA P21397 2/20 0.38
GRIN1 Q05586 3/20 0.37
GRIN2B Q13224 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721383 0.84 ADORA2B (0.37) ADORA1TP53MAPTADORA2BGRIN1
SCHEMBL1721175 0.75 ADORA2B (0.44) ADORA1KDM4EALDH1A1GAANPSR1
SCHEMBL30891822 0.74 ADORA1 (0.63) ADORA1ADORA2BADORA2A
SCHEMBL2684084 0.74 ADORA1 (0.63) ADORA1ADORA2BADORA2A
SCHEMBL1720580 0.69 SCD (0.38) ADORA1ADORA2BGRIN1GRIN2BADORA2A
SCHEMBL13247934 0.66 NR1H4 (0.63) NR1H4TP53MAPTKDM4EALDH1A1
SCHEMBL11428028 0.64 NR1H4 (0.49) NR1H4TP53MAPTALDH1A1TSHR
SCHEMBL30891856 0.63 ADORA1 (0.58) ADORA1ADORA2BADORA2A
SCHEMBL17955921 0.63 MAOB (0.45) NR1H4MAPTKDM4EALDH1A1GAA
SCHEMBL1718941 0.61 KDM4E (0.46) ADORA1MAPTKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3727391-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER Impetis Biosciences Ltd. (IN) 2020-10-28 EP disclosed
EP-2405917-A2 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS Advinus Therapeutics Private Limited (IN) 2012-01-18 EP disclosed
WO-2010103547-A2 SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-09-16 WO disclosed